Home > Journals > Minerva Pediatrica > Past Issues > Articles online first > Minerva Pediatrica 2018 Apr 12

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA PEDIATRICA

A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,764


eTOC

 

Minerva Pediatrica 2018 Apr 12

DOI: 10.23736/S0026-4946.18.05203-9

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Use of a probiotic mixture containing Bifidobacterium animalis subsp. lactis BB12 and Enterococcus faecium L3 in atopic children

Francesco DI PIERRO 1, Isabella BASILE 2, Maria L. DANZA 3, Leo VENTURELLI 4, Raffaele CONTINI 5, Paolo RISSO 6, Maria COLOMBO 7

1 Scientific & Research Department, Velleja Research, Milan, Italy; 2 ASL District 6, Cologno Monzese, Milan, Italy; 3 ASL District 6, Binasco, Milan, Italy; 4 ATS Bergamo, Bergamo, Italy; 5 ATS Milano, Vignate, Milan, Italy; 6 Health Sciences Department, University of Genoa, Genoa, Italy; 7 ATS Milano, Vignate, Milan, Italy


PDF  


BACKGROUND: Imbalance of the human gut microbiota in childhood, mainly due to low gut biodiversity and a low bifidobacterial load, has been suggested as a risk factor for atopy. Administration of Enterococcus faecium L3 in infants has been shown to increase the gut bifidobacterial count. The aim was to verify if a mixture of Bifidobacterium animalis subsp. lactis BB12 and E. faecium L3 could reduce the signs, symptoms and need for drugs in atopic children.
METHODS: We retrospectively analyzed, and compared with controls, clinical outcomes following use of BB12 and L3 strains when administered 3 months before or during the development of signs and symptoms of atopy.
RESULTS: When administered in the 3 months before the development of atopy, the BB12 and L3 strains significantly reduced (p<0.001) rhinitis, watery eyes and cough/bronchospasm. However, reduced efficacy was observed when the mixture was given during the 3 months of atopy. The mixture of strains also significantly reduced the use of oral anti-histamines, inhaled corticosteroids (in the same children in two different years) and oral corticosteroids (in different children in the same year).
CONCLUSIONS: When administered as a prophylactic, the mixture of BB12 and L3 (iNatal Ped®) statistically decreases the signs and symptoms of atopy and reduces the use of drugs. Administration of the same probiotics as treatment after the appearance of atopy is less effective.


KEY WORDS: Allergy - Asthma - iNatal Ped® - Atopic treatments - Rhinitis - Watery eyes - Cough - Bronchospasm

top of page

Publication History

Article first published online: April 12, 2018
Manuscript accepted: April 6, 2018
Manuscript received: January 23, 2018

Cite this article as

Di Pierro F, Basile I, Danza ML, Venturelli L, Contini R, Risso P, et al. Use of a probiotic mixture containing Bifidobacterium animalis subsp. lactis BB12 and Enterococcus faecium L3 in atopic children. Minerva Pediatr 2018 Apr 12. DOI: 10.23736/S0026-4946.18.05203-9

Corresponding author e-mail

f.dipierro@vellejaresearch.com